New drug targets identified in rheumatoid arthritis

Two new drug targets which could revolutionize the treatment of rheumatoid arthritis have been identified by British biotech company C4X Discovery, it has been revealed.

The targets, identified using the company’s innovative genetic analysis technology, Taxonomy3, are from protein families whose function suggests that any resulting drug molecules will have a very different biological impact than existing therapies.

It marks the first major output from Taxonomy3, a mathematical tool that analyses publically available databases to identify previously unknown linkages between genes and disease pathways, since it was acquired as part of a deal with Adorial Ltd in March 2016.